Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 17/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.67 |
| ▸ | PTAFR | P25105 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.47 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316513 | 1.00 | TACR1 (0.67) | TACR1SIGMAR1PTAFRCYP2D6CYP2B6 | |
| SCHEMBL2487458 | 1.00 | TACR1 (0.67) | TACR1SIGMAR1PTAFRCYP2D6CYP2B6 | |
| SCHEMBL3316519 | 1.00 | TACR1 (0.67) | TACR1SIGMAR1PTAFRCYP2D6CYP2B6 | |
| SCHEMBL3314767 | 1.00 | TACR1 (0.67) | TACR1SIGMAR1PTAFRCYP2D6CYP2B6 | |
| SCHEMBL2486644 | 1.00 | TACR1 (0.67) | TACR1SIGMAR1PTAFRCYP2D6CYP2B6 | |
| SCHEMBL3338163 | 1.00 | TACR1 (0.67) | TACR1SIGMAR1PTAFRCYP2D6CYP2B6 | |
| SCHEMBL3313878 | 1.00 | TACR1 (0.67) | TACR1SIGMAR1PTAFRCYP2D6CYP2B6 | |
| SCHEMBL3337797 | 1.00 | TACR1 (0.67) | TACR1SIGMAR1PTAFRCYP2D6CYP2B6 | |
| SCHEMBL5619451 | 0.87 | TACR1 (0.52) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL5619731 | 0.87 | TACR1 (0.52) | TACR1SIGMAR1PTAFRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317666-A1 | Composition Comprising An NK-1 Receptor Antagonist And An SSRI For The Treatment Of Tinnitus And Hearing Loss | GLAXO GROUP LIMITED | 2010-12-16 | — | — | US | disclosed |
| US-20100152446-A1 | Piperidine Derivatives | NERRE THERAPEUTICS LIMITED (GB) | 2010-06-17 | — | — | US | disclosed |
| US-20100105688-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3,5-DIAMINO-6-(2,3-DICHLOPHENYL)-1,2,4-TRIAZINE OR R(-)-2,4-DIAMINO-5-(2,3-DICHLOROPHENYL)-6-FLUOROMETHYL PYRIMIDINE AND AN NK1 | GLAXO GROUP LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| US-20090326032-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090318530-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| EP-1666465-B1 | Composition comprising a tachykinin receptor antagonist and a selective serotonin reuptake inhibitor | GLAXO GROUP LTD (GB) | 2008-05-07 | — | — | EP | disclosed |
| US-7189713-B2 | Piperidine derivatives | GLAXO GROUP LIMITED (GB) | 2007-03-13 | — | — | US | disclosed |
| EP-1666465-A1 | Composition comprising a tachykinin receptor antagonist and a selective serotonin reuptake inhibitor | GLAXO GROUP LIMITED (GB) | 2006-06-07 | — | — | EP | disclosed |
| US-20050176715-A1 | Piperidine derivatives | NERRE THERAPEUTICS LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318530-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | HCRTR1, TACR2, CNR1 | TACR1 4/4885SIGMAR1 35/4885PTAFR 1941/4885 |
| US-20100105688-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3,5-DIAMINO-6-(2,3-DICHLOPHENYL)-1,2,4-TRIAZINE OR R(-)-2,4-DIAMINO-5-(2,3-DICHLOROPHENYL)-6-FLUOROMETHYL PYRIMIDINE AND AN NK1 | KCNJ2, SCN5A, GRIK5 | TACR1 19/4885SIGMAR1 217/4885PTAFR 843/4885 |
| US-20050176715-A1 | Piperidine derivatives | NPSR1, NPY5R, SSTR5 | TACR1 4/4885SIGMAR1 37/4885PTAFR 2560/4885 |
| US-20090326032-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | TACR2, TACR1, KCNH3 | TACR1 2/4885SIGMAR1 28/4885PTAFR 1735/4885 |
| US-20100152446-A1 | Piperidine Derivatives | NPSR1, NPY5R, NPY4R | TACR1 5/4885SIGMAR1 31/4885PTAFR 2477/4885 |
| US-20100317666-A1 | Composition Comprising An NK-1 Receptor Antagonist And An SSRI For The Treatment Of Tinnitus And Hearing Loss | HTR1A, TPH1, HTR5A | TACR1 7/4885SIGMAR1 259/4885PTAFR 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.